ETCTN 10483: Phase Ib trial of erdafitinib (E) combined with enfortumab vedotin (EV) following platinum and PD-1/L1 inhibitors for metastatic urothelial carcinoma (mUC) with FGFR3/2 genetic alterations (GAs).
| Title: | ETCTN 10483: Phase Ib trial of erdafitinib (E) combined with enfortumab vedotin (EV) following platinum and PD-1/L1 inhibitors for metastatic urothelial carcinoma (mUC) with FGFR3/2 genetic alterations (GAs). |
|---|---|
| Authors: | Jain, Rohit K., Ong, Faustine, Faltas, Bishoy Morris, Tagawa, Scott T., Jiang, Di Maria, Heiligh, Jazlyn, Naqvi, Syeda Mahrukh Hussnain, Kim, Youngchul, Pelosof, Lorraine Cheryl, Yang, Yuanquan, Graham, Laura, Arafat, Waddah, Synold, Timothy Walter, Chatwal, Monica Sheila, Zhang, Jingsong, Chadha, Jus, Sonpavde, Guru P. |
| Source: | Journal of Clinical Oncology; 2/20/2025 Supplement 5, Vol. 43, p808-808, 242p |
| Database: | Supplemental Index |
Be the first to leave a comment!